CAS：313368-91-1
Chemical formula: C24H28FN3O

1. Dosage form specifications
Capsule: 42mg
2 Indications
Suitable for treating adult schizophrenia, depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults
3. Usage and dosage
The recommended dose is 42 mg, once a day
4. Variety advantages
A novel small molecule antipsychotic drug with a unique mechanism of action, which can synergistically regulate the transmission of serotonin, dopamine, and glutamine to exert therapeutic effects;
Approved by the FDA for marketing in December 2019 for the treatment of adult schizophrenia, with new indications added in December 2021 for the treatment of bipolar type I or type II related depressive episodes in adults;
It has the effect of improving sleep quality and reducing negative symptoms of schizophrenia. It also has a certain effect on depression, anxiety, and other symptoms related to impaired social function;
Compared with risperidone, the risk of weight gain is reduced by 13%, and research results show that switching to lumepirone can significantly improve the patient's weight gain. At the same time, this product will not increase the risk of diabetes and cardiovascular disease, so it has obvious advantages in long-term safety and tolerance compared with many existing antipsychotic drugs;
Capsules are the 60th batch of reference materials, without compound patents. The original research has not been imported into China. There is a domestic company that has applied for Class 3 capsules. Our company can provide general agents for foreign raw materials. Please feel free to inquire.